SynthesisBMC cancer2014

Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.

Benjamin Haaland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.